CD274 and non-small cell lung carcinoma: Results of a recent study also drawing on the Flatiron Health database indicated that among patients with nonsquamous NSCLC and PD-L1 expression ≥50% treated with first-line pembrolizumab monotherapy, never-smokers had shorter rwPFS and OS than smokers (28), similar to findings in clinical trials and other observational studies (30, 31).